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Systemic Lupus Erythematosus (SLE) is an acquired, multiorgan, autoimmune disease. Clinical presentation is extremely
variable and heterogeneous. It has been shown that SLE itself is an independent risk factor for developing both arterial
and venous thrombotic events since SLE patients have an Odds Ratio (OR) for thrombosis that varies depending on
the clinical and laboratory characteristics of each study cohort. The risk of developing a thrombotic event is higher in
this setting than in the general population and may further increase when associated with other risk factors, or in the
presence of inherited or acquired pro-thrombotic abnormalities, or trigger events. In particular, a striking increase in the
number of thrombotic events was observed when SLE was associated with antiphospholipid antibodies (aPL).
The presence of aPLs has been described in about 50% of SLE patients, while about 20% of antiphospholipid syndrome
(APS) patients have SLE. While APS patients (with or without an autoimmune disease) have been widely studied in the
last years, fewer studies are available for SLE patients and thrombosis in the absence of APS. Although the available
literature undoubtedly shows that SLE patients have a greater prevalence of thrombotic events as compared to
healthy subjects, it is difficult to obtain a definite result from these studies because in some cases the study cohort was
too small, in others it is due to the varied characteristics of the study population, or because of the different (and very
copious) laboratory assays and methods that were used. When an SLE patient develops a thrombotic event, it is
of great clinical relevance since it is potentially life-threatening. Moreover, it worsens the quality of life and is a
clinical challenge for the clinician.
Keywords: Systemic lupus erythematosus, Thrombosis, Risk factorsIntroduction
Systemic Lupus Erythematosus (SLE) is an acquired, mul-
tiorgan, autoimmune disease. The clinical presentation is
extremely variable and heterogeneous with regard to the
possible involvement of various organs and systems, to
the varying severity of the clinical picture, and to the ab-
normalities (when present) of laboratory tests. Diagnosis
is often complex, and both clinical and laboratory criteria
are usually used. Criteria for the diagnosis of SLE were
first published in 1971, while the SLICC (Systemic Lupus
International Collaborating Clinics) 2012 criteria are
currently used to diagnose SLE (see Table 1) [1-5]. SLE
mainly affects women in their childbearing years and may
potentially affect any organ or system apparatus. The cal-
culated prevalence is about 20-150/100,000 [6,7], mainly
affecting people between 15 and 44 years of age, with a
two-fold prevalence for black women [8,9]. On average,
Hispanics and African-Americans are diagnosed with SLE* Correspondence: bazzmar@yahoo.com
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unless otherwise stated.at a younger age and with more severe forms of
the disease than Caucasians. Cervera [10] showed that
10-year survival in a cohort of 1,000 SLE patients was
90%, and that 25% of the deaths were secondary to active
disease, to thrombotic events, or to intercurrent infections.
Recently, other authors [11] calculated a 10-year survival
rate of 70%. According to some authors, thrombotic events
and cardiovascular accidents are the first complications of
SLE after reactivation (“flares”) of the disease and infec-
tions [12]. It has been widely described that SLE itself is an
independent risk factor for developing arterial and venous
thrombotic events since SLE patients have an Odds Ratio
(OR) for thrombosis that varies depending on the clinical
and laboratory characteristics of each study cohort. The
risk of developing a thrombotic event, which is higher in
this setting than in the general population, could further
increase when associated with other general, demographic
risk factors, or in the presence of inherited or acquired
pro-thrombotic abnormalities or of triggering events (such
as infections) [13,14]. Thrombotic events are not in-
cluded in the diagnostic criteria for SLE (see Table 1),l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 SLE diagnostic criteria (modified from [1])
Systemic lupus erythematosus: diagnostic criteria (2012 – SLICC)







Joints – 1 Item Synovitis > 2 peripheral joints
(pain, tenderness, swelling or
morning stiffness > 30 min)
Serositis – 1 item Pleuritis, typical pleurisy ≥ 1 day,
history, rub, evidence of pleural
effusion, pericarditis, typical
pericardial pain ≥ 1 day, EKG
evidence of pericardial fusion)
Renal disorder – 1 Item Urine protein/creatinine ratio or
urinary protein concentration of
0.5 g of protein/24 h, Red blood
cell casts
Haematological disorder – 3 Items Haemolytic anaemia
Leukopenia (<4000/mm3) or
lymphopenia (<1000/mm3)
separately at least once
Thrombocytopenia (<100,000/mm3)
at least once
Immunologic abnormal – 6 Items Positive ANA
Positive anti-dsDNA (except ELISA)






Low complement (C3, C4 or CH50)
Direct Coombs test in the absence
of haemolytic anaemia
Diagnosis Fulfil 4 items (at least one clinical
and one immunologic item)
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ious complication of the natural history of the disease,
they have been studied in SLE patients both from a phys-
iopathological and from a clinical point of view in an ef-
fort to define the therapeutic strategies of prevention and
treatment (secondary prevention). In particular, in 1983, a
striking increase in thrombotic events was described when
the associated presence of anti-phospholipid antibodies
(aPL) was observed in SLE patients [15]. The antipho-
spholipid syndrome (APS) [16] is characterized by the
presence of arterial or venous thrombotic events and/or
by serious obstetrical complications associated with the
persistent presence of aPLs in the serum. “Lupus anticoagu-
lant” (LA) testing identifies the presence of aPLs in the
serum that is evaluable by coagulation tests (historicallyaPTT-based). This name was given since it was initially
found in patients with “lupus” and that it prolonged
the aPTT, thus simulating the presence of a circulating
anticoagulant. The current classification criteria were
defined in 2005 at the Consensus Conference of Sydney
(see Classification criteria for the APS) [17]. APS can
be diagnosed in patients with or without a previously
diagnosed autoimmune disease, such as SLE. aPLs have
been widely shown to be a significant and independent
risk factor for thrombotic events and obstetric complica-
tions. It is extremely important to identify the characteris-
tics of aPL positivity according to the Sydney criteria.
Three laboratory tests must be performed i.e., LA by
functional tests, and anticardiolipin antibodies (ACL) and
anti-beta2-GP1 antibodies (anti-β2-GP1) by immunoassay,
evaluating both IgG and IgM isotopes. If at least one of
the tests is positive [18], it must be confirmed at least
12 weeks after the first assay. A “high titre” of antibodies
in the serum, which needs to be confirmed over time,
must be present (see classification criteria) to define the
positivity of the result. Recently, the term “aPL profile”
has been used to define the number and type of positive
tests: the higher the number of positive tests, the higher
the thrombotic risk. “Triple positivity” (LA plus ACL plus
anti-β2-GP1) has the strongest prognostic value in terms
of thrombotic events and recurrences [19-21]. Current
consensus on classification criteria recommends stratify-
ing the risks faced by APS patients according to their
laboratory profile. The overall risk of thrombotic recur-
rences in APS patients should be stratified considering
both clinical and laboratory features. Furthermore, the
presence of associated SLE has been considered a factor
of “higher risk” for these patients. The presence of aPLs
has been described in about 50% of SLE patients, while
about 20% of APS patients have SLE [22,23]. Ultimately,
when an SLE patient develops a thrombotic event, it
is of great clinical relevance since it is potentially life-
threatening. Moreover, it worsens the quality of life and
is a challenge for the clinician. Herein, we will described
some aspects of the association of SLE and thrombosis.
Classification criteria for the APS (modified from [17])
Clinical criteria
1) Vascular thrombosis: one or more clinical episodes
of arterial, venous or small vessel thrombosis in any
tissue or organ confirmed by imaging or Doppler
studies or histopathology (except superficial venous
thrombosis, except histopathological evidence of
vasculitis)
2) Pregnancy morbidity:
a) one or more unexplained deaths of a
morphologically normal foetus > 10th week
of gestation, or
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morphologically normal neonate < 34th week
of gestation because of eclampsia, preeclampsia
or placental insufficiency, or
c) three or more unexplained consecutive
spontaneous abortions <10th week of gestation
with the exclusion of anatomical, hormonal,
chromosomal parental abnormalities.Laboratory criteria
1) anticardiolipin antibody IgG and/or IgM isotype in
serum or plasma present in medium or high titre
(i.e., >40 GPL or MPL or >99th percentile) on 2 or
more occasions at least 12 weeks apart
2) lupus anticoagulant present in plasma on 2 or more
occasions at least 12 weeks apart
3) anti-beta2 glycoprotein-1 antibody of IgG and/or
IgM isotype in serum or plasma, present on 2 or
more occasions at least 12 weeks apart
Definite APS: one clinical criteria and one laboratory
criteriac present with first measurement of the labora-
tory test performed at least 12 weeks from clinical
manifestationd.
acoexisting inherited or acquired factors for thrombosis
are not reasons for excluding patients from APS trials.
Two subgroups of APS patients should be acknowledged
according to 1) presence or 2) absence of additional risk
factors for thrombosis.
binclude 1) abnormal or non-reassuring foetal surveil-
lance tests 2) abnormal Doppler flow velocimetry waveform
analysis suggestive of foetal hypoxaemia 3) oligohydramnios
4) post natal birth weight less than 10th percentile for
gestational age investigators should classify APS patients
in I) more than one laboratory criteria present or IIa)
ACA present alone or IIb) LA present alone or IIc) anti-
beta2GP-I ab present aloned if less than 12 weeks or more
than 5 years have gone by since clinical manifestation and
confirmation of aPL positivity, then APS should not be
defined.Search strategy
To identify all available studies, a detailed search per-
taining to Systemic Lupus Erythematosus and thrombosis
was conducted. A systematic search was performed in the
electronic database (PubMed –NCBI) using the following
search terms in all possible combinations: systemic lupus
erythematosus, arterial thrombosis, vein thrombosis, risk
factor, antiphospholipid antibodies, inherited thrombo-
philia, acquired thrombophilia, cardiovascular disease, ath-
erosclerosis, ethnicity, treatment, antithrombotic treatment,
antithrombotic prophylaxis, pregnancy, contraception,catastrophic APS. The last search was performed the
16th January, 2014.
Physiopathology of atherosclerosis and arterial
thrombosis in SLE
Atherosclerosis is a pathological process characterized by
the formation of fibro-fatty deposits in the intima layer
of large and medium calibre arteries. It is recognized as
the most frequent cause of death in Western countries
[24]. Studies conducted in the 70's on patients with SLE
showed that a bimodal mortality pattern (at 1 year and
8 years after diagnosis) may be observed in patients with
SLE. The first peak is due to the disease and to the infec-
tious complications, while the second peak, in the phase
of quiescent disease, is due to the long-term glucocortic-
oid therapy and to cardiovascular morbidity [25]. Over the
years there has been a decrease in the number of deaths
occurring in the first year after diagnosis, mainly due to
the increased effectiveness of the therapies and especially
to the prevention of end-stage renal disease, while the
mortality for cardiovascular disease (CVD) has not de-
creased [26] (relative risk compared to the general
population for non lethal myocardial infarction RR 10.1,
for fatal cardio-coronary heart disease RR 17, for stroke
RR 7.9) [27]. A study by the Karolinska Institute [28] on a
cohort of SLE patients showed that 50% of SLE patients
died of some form of CVD. The main consequences of
atherosclerosis in SLE patients include myocardial infarc-
tion, stroke and peripheral vascular disease [29]. The pres-
ence of atherosclerosis for the stratification of CVD risk
was evaluated by Doppler ultrasound which was used to
search for and measure carotid plaques and to measure
carotid intima media thickness (IMT), while Electron-
Beam Computed tomography (EBTC) was used to evalu-
ate the calcium score in the coronary vessels [29]. Results
showed early and accelerated onset of atherosclerosis in
SLE patients (40% vs. 6-10% of a homogeneous sample
among controls) [30,31]. This is associated with the early
onset of cardiovascular disease (first event 47–64 years of
age) [32], even in pre-menopausal women, thus resulting
in a 2- to 10-fold greater risk of developing cardiovascular
disease [29] as compared to the general population. There
are currently no studies quantifying the burden of early
onset atherosclerosis as compared to the development of
future cardiovascular events [33]. Atherosclerosis in SLE
patients is favoured both by general risk factors and by
SLE-related risk factors. General risk factors include age,
sex, arterial hypertension, dyslipidemia, obesity, genetic or
acquired thrombophilia and ethnicity [34]. The presence
of diabetes in SLE patients is surprisingly little-studied:
data from a study carried out at Johns Hopkins [35] sug-
gest a two-fold risk of cardiovascular disease. Lastly, the
lack of vitamin D [36] in SLE patients has been linked
to an increase in atherosclerotic plaques, to high disease
Bazzan et al. Thrombosis Journal  (2015) 13:16 Page 4 of 10activity, to a high body mass index and to the presence of
dyslipidemia and insulin resistance. A high homocysteine
level is an independent risk factor [37]. The risk factors
that are directly related to the pathology (see Table 2) are
linked to extensive immune dysregulation, to systemic
inflammation, and to endothelial dysfunction (partly medi-
ated by autoantibodies) [29]. SLE patients are known to
undergo changes in their lipid profiles, which are mediated
by the pro-inflammatory activation of TNF-alpha [29],
MCP-1 and IL-6 [38]. Total cholesterol and triglycerides in-
crease, while HDL decreases and loses its anti-inflammatory
and scavenger characteristics due to an immune-mediated
mechanism. It then becomes pro-inflammatory (piHDL)
[39] and correlates to an increased risk of coronary heart
disease. It has recently been shown that serum choles-
terol efflux capacity (CEC) is impaired in SLE patients
thus increasing the atherosclerotic risk of these subjects
in a non dependent way with respect to serum HDL
levels [40]. Increased lipid oxidation has been reported in
these patients [41]. Concomitant nephropathy may con-
tribute to further worsening dyslipidemia. The mechanisms
underlying endothelial dysfunction are present from the
early stages of the disease with increased expression of
cell adhesion molecules (ICAM, VEGF, Von WillebrandTable 2 Factors influencing atherosclerosis and


















IL-17, IL-12, IL-18 elevation,
IgG overexpression
Pro-inflammatory




Higher risk of CVD
Medications Effects
Corticosteroids Higher risk of CVD
Antimalarial (OH-chloroquine) Anti-thrombotic, anti-inflammatory,
anti-dyslipidemic




Fewer autoantibodies and improvement
of kidney function in animal models, to
be confirmed in humans
NSAIDs Higher risk of CVD (less with naproxene)factor, VCAM) which are associated with the develop-
ment of CVD in SLE [32]. The increased expression of
Von Willebrand factor (mediated by the production of
inflammatory-cytokines) also has a pro-aggregating effect
[42]. It has been demonstrated that SLE patients are un-
able to degrade the NETs (neutrophil extra-cellular traps)
complex which regulates apoptotic processes [43]; NETs
emerge as a possible mediator of vascular damage and an
activator of the thrombotic process. The increase in in-
flammatory interleukins (IL-17, IL-12 and IL-18) [44], the
altered response of B lymphocytes and the production of
IgG class autoantibodies with pro-inflammatory meaning
[45], and the selective deficiency of T reg lymphocytes
are all mechanisms that are present in SLE patients and
are associated with an increased risk of CVD [24]. High
disease activity is linked to earlier onset of cardiovascular
damage, to a worse prognosis (because of the increased
risk of CVD), to the increase in IMT thickness (early ath-
erosclerosis) and to the presence of arthritis-serositis
(a sign of greater systemic inflammation with increased
risk of CVD) [29]. The presence of antibodies to SS-A and
SS-B is usually associated with less active disease, but
these patients have a pattern of CVD damage and related
mortality that is significantly worse [29]. The nephrotic
syndrome is correlated with an increased thrombotic risk.
In a wide, recently performed meta-analysis on case–con-
trol studies of APS patients, APS itself was shown to be
related to markers of subclinical atherosclerosis and endo-
thelial damage [46]. In a systematic review on the main
predictors of cardiovascular events in SLE patients, [47],
the presence of autoantibodies and of neurological disor-
ders were found as “non traditional” risk factors, with an
OR of about 5 in both cases. A polymorphism in the toll-
like receptor 2 (TLR2) has recently been linked to the
pathogenesis of thrombosis in SLE patients. In particular,
African Americans and European Americans show an as-
sociation between TLR2 mutation and thrombosis [48].
Treatment may have an effect on thrombotic risk. Steroids
have been reported to increase the atherogenic risk in two
ways: the first (direct) via plasma lipoproteins, the second
(indirect) by favouring hypertension, diabetes and hyper-
lipidemia. Moreover, the cumulative dose of steroids, more
than the daily dosage alone, seems to be related to the de-
velopment of atherosclerosis. [49-51]. Antimalarials have an
anti-thrombotic, anti-inflammatory effect and control dys-
lipidemia [52]. Moreover, by blocking toll like receptors
7 and 9, hydroxychloroquine inhibits interferon alpha pro-
duction which plays a pathogenetic role in SLE pathogen-
esis [53]. Mycophenolate mofetil reduces the activation of
T lymphocytes and increases the presence of regulatory T
lymphocytes in carotid plaques [52]. An animal model of
SLE showed that Atorvastatin reduces the level of autoanti-
bodies and improves proteinuria and renal histology, how-
ever, there is still no general consensus for its extensive use
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inflammatory drugs (NSAIDs) may increase cardiovascu-
lar risk (rofecoxib is associated with a greater risk of
myocardial infarction, ibuprofen is associated with a higher
risk of stroke, diclofenac with higher cardiovascular tox-
icity, naproxen seems to be the least harmful [54] though
it can worsen kidney function. The therapeutic strategy for
lowering the risk of CVD should be aimed at an even more
aggressive treatment of the disease during the active phase
[24]. Other emerging indications include: the immediate
cessation of smoking, the use of hydroxychloroquine in
all SLE patients who do not have contraindications to
such treatment, the use of statins for dyslipidemia, the
treatment of arterial hypertension (SBP <120 mmHg), and
therapy with acetylsalicylic acid (ASA) which may be
useful in SLE patients with general or lupus-related CVD
risk factors. The role of immunosuppressive agents in
the prevention of atherosclerosis is tentative and must
be further investigated [24].
Clinical risk factors for thrombosis in SLE: prevention and
treatment
The clinical risk factors for thrombosis
In SLE have been widely studied. A recent Swedish study
[32] showed that in a cohort of 182 SLE patients (with an
average follow-up of 8.3 years) who have not had a throm-
botic event, 13% developed a cardiovascular event (CVE).
CVE events included: ischaemic heart disease (IHD),
ischaemic cerebrovascular disease (ICVD), ischaemic
peripheral vascular disease (IPVD), or death related to
a thrombotic event. The authors concluded that the
presence of aPLs increased the Von Willebrand factor,
and that the absence of thrombocytopenia significantly
correlated to a higher risk of developing an ischaemic
event. Retinal vein occlusion is reportedly more frequent
in patients with SLE compared to an age-matched control
group, with a Hazard Ratio (HR) = 3.883 [55]. Age above
50 years was an independent risk factor, with an HR = 4.8.
[55]. A higher incidence of thrombotic events has been
reported in SLE patients with lupus nephropathy (LN)
[56]. Twenty-five thrombotic events were observed in a
cohort of 200 SLE patients who had LN. Sixty-eight % of
the events were venous, with an overall incidence of
thrombotic events of 29.1 per 1,000 patients/year. The
concomitant presence of aPLs (odds ratio 126!), or of
sierositis (OR 5), and a history of arterial thrombosis
(OR 24) was associated with thrombotic events, while
treatment with ACE inhibitors showed a protective
effect. Chung et al. evaluated the incidence of venous
thromboembolic events in a large Chinese SLE cohort
(13,084 patients) and compared it to that of a healthy
control group without SLE [57]. After adjusting for age,
sex and comorbidities, the risk of developing a deep vein
thrombosis (DVT) or a pulmonary embolism (PE) in theSLE patient group was found to be 12.8 and 19.7, respect-
ively, as compared to the control group. The risk of devel-
oping IHD, coronary artery disease (CAD) and stroke was
calculated in another large cohort of 2,000 patients
enrolled in Sweden that included 277 subjects who had
American College of Rheumatology (ACR) criteria > 4 [58].
They found an 8- to 9-fold greater risk in middle-aged
women with respect to the control population. The pres-
ence of IgG ACL was predictive of thrombotic events. A
meta-analysis concerning different clinical variables that
predict a cardiovascular event in SLE patients was carried
out [47]. After a median follow up of 8 years, a prevalence
of 25.4% of new thrombotic events was calculated, of
which 4% were IHD and 7% were strokes. In this study,
the most significant risk factors that were found were
male gender, dyslipidemia, family history for CAD, and
arterial hypertension, while the presence of autoantibodies
and neurological disorders were among the “specific” risk
factors. Low correlation was found with respect to organ
damage and disease activity. Infectious episodes per se
could represent an additional risk factor for thrombosis
[59,60] in SLE patients. In the last few years, “scores” to
calculate the risk of thrombosis in SLE patients have been
devised and proposed. Available literature clearly shows
that SLE patients have a greater prevalence of thrombotic
events with respect to healthy subjects. However, it is diffi-
cult to obtain definitive results from these studies because
in some cases the study cohort was too small, in other cases
it was due to the different characteristics of the study popu-
lation, or even because of the different (and very copious)
laboratory assays and methods that were used.
Primary prevention of venous thromboembolism (VTE)
Although SLE per se seems to be a risk factor for throm-
bosis, mainly in the active phases, it is not generally men-
tioned as a risk factor in the more common risk assessment
models (RAM) for medical thromboprophylaxis [61], such
as the Caprini RAM [62] or Rogers scores [63]. The pres-
ence of LA and of ACL are instead mentioned in these
RAM as risk factors. Moreover, the Padua Prediction score
risk assessment model [64] also mentions the presence of
APS among thrombotic risk factors (regardless of whether
it is primary or secondary), thus increasing the score itself.
In the absence of available guidelines in this clinical setting,
we believe that SLE patients must be considered at higher
thrombotic risk, even in the absence of APS and aPLs,
mainly during the active phases.
VTE and arterial thrombosis treatment
Based on current guidelines, treatment of the acute
phase of VTE is no different in these patients from the
standard treatment [65]. A higher intensity of anticoagu-
lation therapy (INR 3–4 or low dose ASA associated to
avK with an INR range 2–3) (see Table 3) has been
Table 3 Treatment recommendations for patients with
SLE, associated or not with aPLs or APS, and thrombosis
(modified from [14])
Clinical scenario Recommendations
Patients with definite APS (+/− SLE)
and first venous event
aVK, INR range of 2.0-3.0
Patients with definite APS (+/− SLE)
and venous recurrent thromboembolism
during aVK or arterial thrombosis*
aVK, target INR > 3.0a
or
combination of aspirin
(100 mg daily) and aVK,
INR range 2.0-3.0a
APS patients (without SLE) with a
first non cardioembolic cerebral
arterial event, low-risk aPL profile,
and reversible predisposing factors
Antiplatelet agents
SLE patients with venous or arterial
thrombosis who do not fulfil APS
laboratory classification criteria
Same as patients from the
general population who
develop venous or arterial
thrombosis
aThere was a lack of consensus on these recommendations.
APS, antiphospholipid syndrome; INR international normalized ratio; SLE,
systemic lupus erythematosus; aPL, antiphospholipid antibodies.
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venous thrombotic recurrence or with arterial events. If
indicated, direct oral anticoagulants (dabigatran, rivaroxa-
ban or apixaban) could be used for VTE. Results from
studies focusing on this clinical setting are not yet avail-
able, though they are in progress. Clinicians must take
into consideration that SLE patients often have renal
disease and chronic kidney failure, thus there is a need
to avoid these drugs or to reduce the doses, according
to the manufacturer’s recommendations. The possible
association with NSAIDs must also be considered because
of the increased bleeding risk. Concerning the optimal
duration of anticoagulant treatment, no definite evidence
or guidelines are currently available. Considering that a
persistent risk of thrombosis is present in these patients,
mostly in subjects with SLE and APS, long term anticoa-
gulation is recommended. Shorter anticoagulant treat-
ment should be considered for patients with SLE alone
after the first venous thrombotic event, or if SLE is associ-
ated with a low risk aPL profile provided that SLE is not
in an active phase and that the thrombosis had a well-
defined, transitory trigger event. Thrombotic and bleeding
risk assessment must be carried out periodically in all of
these patients, both at the start of treatment and then
at least every year after that. Further evaluation must be
performed in case of intercurrent pathologies, or if new
drugs to treat SLE are introduced.
Primary prevention of acute arterial diseases
Good quality evidence is also missing in this setting. Some
consensus exists [66-69] concerning the use of low dose
ASA (i.e., 100 mg daily) in patients with SLE and aPLs who
have never had a thrombotic event. Even in the absenceof aPLs, associated risk factors such as age, smoking,
hypertension, obesity, dyslipidemia, etc. must be taken into
consideration when starting primary arterial prevention.
Pregnancy, contraception and thrombosis
Pregnancy in SLE patients carries a burden of increased
risk of morbidity and mortality, both for the mother and
for the foetus/newborn [70]. The most frequently reported
drawbacks include: pre-eclampsia, pre-term delivery, ven-
ous and arterial thrombosis, infections, haematological
complications (cytopenias, mainly thrombocytopenia). In-
creased mortality has been described in this clinical setting
[71]. As already reported, a high percentage of SLE pa-
tients have aPLs. [70] Furthermore, if these subjects are
still asymptomatic (no previous thrombotic event or ob-
stetrical complication), they are at high risk of miscarriage
and pregnancy morbidity. In particular, LA positivity [72]
proved to have strong positive predictive value for an
adverse event during pregnancy. It was recently demon-
strated that by using appropriate pharmacological strat-
egies, it is possible to significantly increase the probability
of good pregnancy outcome up to 80% of live born babies
[70,22]. In SLE patients with asymptomatic aPL positivity,
low dose ASA (100 mg/die) is recommended [73]. Low
dose ASA associated with LMWH at prophylactic doses
(i.e., 4000 U/die) is recommended for SLE with obstetrical
APS (miscarriages or foetal loss), but no previous throm-
botic event [74,75]. For SLE patients with vascular APS
(i.e., a previous thrombotic event), therapeutic LMWH
doses (i.e., 100 U/Kg twice a day) are recommended
throughout pregnancy and puerperium. Warfarin must
be avoided during pregnancy, particularly during the
first trimester; data concerning treatment with fondapari-
nux are scant but encouraging for LMWH-intolerant pa-
tients [76]. In the presence of a venous thrombotic event
during pregnancy, therapy with full doses of LMWH are
recommended, and if possible, factor Xa should be evalu-
ated in order to adjust LMWH dosage. LMWH treatment
must be discontinued at least 24 hours before delivery
(induction or caesarean section) [77]. LMWH treatment
must be extended at least until the 6th week after delivery.
Possible further extension of the anticoagulant treatment
must be evaluated for each individual patient taking into
consideration the presence of aPLs, the aPL profile, the
degree of SLE activity, and the degree and quality of the
resolution of the thrombotic event. In the clinical context
of SLE patients, it is extremely important to provide these
patients with information concerning the best contracep-
tive approach in order to schedule a pregnancy during a
stable phase of the disease, and while on drugs that are
not contraindicated in pregnancy. Contraceptives contain-
ing progesterone alone (progesterone intrauterine devices
or drugs) should be considered preferable and safer in
SLE patients. Oestro-progestin preparations must be used
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disease, but are contraindicated in patients with a previous
thrombotic event or in the presence of aPLs [78].
Catastrophic APS
Since a high percentage of patients with SLE are also af-
fected by secondary APS, in this paragraph we will describe
a severe and acute thrombotic syndrome that may compli-
cate the outcome of patients affected by APS. Catastrophic
APS (CAPS) is a rare and life-threatening form of APS and
is characterized by the involvement, over a very short time
(less than a week), of several organs/tissues as the target of
intravascular thrombosis of microcirculation. The diagnos-
tic criteria for CAPS include: 1) involvement of three or
more organs/tissues 2) occurrence of events in less than a
week 3) histological evidence of intravascular thrombosis
4) the presence in the patient’s serum/plasma of antipho-
spholipid antibodies (see Criteria for the classification of
catastrophic APS [79]). A previous diagnosis of APS and/
or the persistence of clinically significant aPL positivity is
useful in the diagnosis of CAPS, however, nearly half of the
patients who develop CAPS do not have a history of
aPL positivity [80]. CAPS is predominantly characterised
by widespread thrombosis of the microcirculation, even
though arteries, veins or both may also be involved in the
thrombotic process. Histological specimen investigation
shows acute thrombotic microangiopathy with inflamma-
tory infiltrate in the interstitial space in one third of cases,
immunofluorescence shows strong immunoreactivity and
anti-fibrin antibodies, while immune complex deposition
is uncommon [81]. An analysis of a large cohort showed
that these patients are mainly female (72%) with a mean
age of 37 years. Triggering events, such as infections, sur-
gery, discontinuing anticoagulant therapy, medications,
obstetric complications or malignancy are usually identifi-
able [22]. A pre-existing condition of autoimmune disease
is quite common (SLE in 40% of patients). CAPS is often
accompanied by a systemic inflammatory response syn-
drome likely due to the extremely extensive tissue damage
[82]. Laboratory examinations show positivity in the ma-
jority of patients for LA and ACL.
Antinuclear antibodies (ANA) are present in approxi-
mately two thirds of patients even though titres are not as
high (<1: 320). There may be non-severe thrombocytopenia
and haemolytic anaemia (about one third of patients), while
the presence of a significant number of schistocytes in the
peripheral blood smear is observed in only about one-tenth
of patients, probably due to the high speed with which
they establish the thrombotic process involving the micro-
circulation [83]. Differential diagnosis primarily includes
haemolytic-uraemic syndrome, thrombotic thrombocyto-
penic purpura, disseminated intravascular coagulation and
heparin-induced thrombocytopenia (HIT). Bleedings and
infections often complicate the course of the diseaseresulting in a worse prognosis. Recent data show a decrease
in mortality from 53% to 33% due to a combination of
therapeutic strategies in association; these associations in-
clude anticoagulants (mainly heparin, which also inhibits
complement activation), antiplatelet agents, corticosteroids,
plasma-exchange (useful for removing pathological aPLs,
cytokines and complement and also incorporating natural
anticoagulants like antithrombin and protein C), cyclo-
phosphamide (which could be useful in patients with
active autoimmune disease or systemic vasculitis), rituxi-
mab (quite promising, especially in patients with severe
thrombocytopenia) and high-dose i.v. immunoglobulin
(this treatment is based on its ability to block pathological
antibodies, to increase clearance, to act on the comple-
ment system and to suppress cytokines). Recently, long-
lasting remission was obtained in a patient with recurrent
CAPS by inhibiting the terminal complement with eculi-
zumab, a recombinant humanized monoclonal IgG2/4
antibody that selectively targets and inhibits the ter-
minal portion of the complement cascade [84]. CAPS
patients require adequate management in the intensive
care unit which should include haemodialysis, mechanical
ventilation or cardiovascular support for shock.Criteria for the classification of catastrophic APS
(modified from [79])
Definite catastrophic APS: All 4 criteria
 Evidence of involvement of three or more organs,
systems and/or tissues.a
 Development of manifestations simultaneously or in
less than a week.
 Confirmation by histopathology of small vessel
occlusion in at least one organ or tissue.b
 Laboratory confirmation of the presence of
antiphospholipid antibodies (lupus anticoagulant
and/or anti-cardiolipin antibodies).Probable catastrophic APS:
 All 4 criteria except for the involvement of only two
organs, systems and/or tissues
 All 4 criteria except for the absence of laboratory
confirmation at least 6 weeks apart due to the early
death of a patient never tested for aPLs before
catastrophic APS
 1, 2 and 4
 1, 3 and 4 and the development of a third event in
more than a week but less than a month, despite
anticoagulation
aVessel occlusion confirmed by imaging techniques, renal
involvement defined as a 50% rise in serum creatinine,
Bazzan et al. Thrombosis Journal  (2015) 13:16 Page 8 of 10severe systemic hypertension (>180/100 mmHg) and/or
proteinuria (>500 mg/24 h).
bSignificant evidence of thrombosis must be present
for histopathological confirmation, and vasculitis may
coexist.
cIf not present, previous diagnosis of APS lab confirm-
ation requires the presence of antiphospholipid antibodies
which must have been detected on two or more occasions
at least 6 weeks capart (not necessarily at the time of the
event), according to the proposed preliminary criteria for
the classification of definite APS.
Conclusions
A great deal of physiopathological data concerning SLE
and thrombosis is available. Unfortunately, as far as the
clinical approach in this setting is concerned, few guide-
lines are available and however, are not based on strong
evidence. These patients are generally very complicated,
and consequently are often treated with an association of
multiple drugs. Moreover, SLE patients often have cytope-
nias, mainly thrombocytopenia, and this complicates the
anticoagulant strategies and their standardization. Starting
from these premises, the presence of well performed clin-
ical studies in this setting is an unmet clinical need.
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